Cell News and Research

RSS

Corning acquires Plaslab

Corning Incorporated announced today that it has completed the previously announced acquisition of all outstanding shares of Plaslab S.A.S. from certain investment funds managed by Qualium Investissement and from the other shareholders of Plaslab. Plaslab is the holding company of Plastiques Gosselin.

4 Oct 2010

Onconova enters agreement with FDA for Estybon Phase 3 trial SPA

Onconova Therapeutics®, Inc. announced agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) for the design of a pivotal Phase 3 trial for Estybon™ (ON 01910.Na) as monotherapy in patients with myelodysplastic syndromes (MDS), diseases affecting the production of healthy blood cells in the bone marrow.

4 Oct 2010

Mylan subsidiary receives FDA approval for Fludarabine Phosphate Injection ANDA

Mylan Inc. today announced that its subsidiary Bioniche Pharma received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Fludarabine Phosphate Injection USP, 25 mg/mL, packaged in 50 mg/2 mL Single-dose Vials. The product was determined to be bioequivalent and, therefore, therapeutically equivalent to Teva Parenteral's Fludarabine Phosphate Injection USP, 25 mg/mL, a chemotherapy medication for B-cell chronic lymphocytic leukemia (CLL).

4 Oct 2010

JASH journal added to MEDLINE collection

Elsevier announces that the Journal of the American Society of Hypertension (JASH) has been selected for inclusion in MEDLINE. MEDLINE is the premier bibliographic database of the U.S. National Library of Medicine (NLM), containing over 15 million journal article citations, with a concentration on biomedicine.

4 Oct 2010

Merck's boceprevir Phase III studies for HCV to be presented at 61st AASLD

Merck today announced that final results from two pivotal Phase III studies of boceprevir, its investigational oral hepatitis C protease inhibitor, will be presented in oral plenary sessions at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), which is taking place from Oct. 29 through Nov. 2 in Boston. Results for boceprevir in response-guided therapy strategies, which evaluated treatment durations shorter than current standard therapy, will be presented during the meeting.

4 Oct 2010

Advanced BioHealing to present industry experience at 2010 World Stem Cell Summit

Advanced BioHealing, Inc. (ABH), a leader in commercializing the promise of regenerative medicine, announced that Senior Vice President, Dean Tozer and Vice President of Government Affairs and Health Economics, Therésa Dixon will speak on behalf of the Company at the 2010 World Stem Cell Summit, sharing their more than 30 years of combined industry experience with attendees.

4 Oct 2010

Noninvasive embryo assessment technology may improve success rates for in vitro fertilization procedures

Auxogyn, Inc., a privately held medical technology company focused on women's reproductive health, today announced that it acquired an exclusive license from Stanford University to develop a set of products that may allow medical practitioners in the field of assisted reproduction to significantly improve the effectiveness of in vitro fertilization (IVF) procedures.

4 Oct 2010

Rate of chemotherapy administration for NSCLC more than twice that reported by SEER

For the first time to date, research published in the October edition of the Journal of Thoracic Oncology (JTO) sought to determine the use of chemotherapy in a contemporary, diverse non-small cell lung cancer (NSCLC) population encompassing all patient ages. Prior population-based studies have shown that only 20 to 30 percent of advanced lung cancer patients receive chemotherapy treatment.

4 Oct 2010

NIH to award $64M under Transformative Research Projects program

The National Institutes of Health will award up to $64 million over five years to encourage exploration of exceptionally innovative and original research ideas that have the potential for extraordinary impact.

4 Oct 2010

Study demonstrates potential of nontoxic envelope proteins as an alternative to pseudotype lentiviral vectors

Therapeutic lentiviral vectors are emerging as vital tools for molecular medicine as evidenced by the growing number of clinical trials using these vector systems. From a basic research standpoint, lentiviral vectors are very intriguing substrates. On the one hand, the HIV-1 genome offers expanded cloning capacity and the capability to transduce nondividing cells such as hematopoietic stem cells (HSCs) and neurons.

4 Oct 2010

Benitec announces USPTO's reversal of all previous rejections in '099 Graham patent appeal

Benitec Limited, a leading Australian based company specialising in RNA interference (RNAi) technology is pleased to announce the United States Patent and Trademark Office's (USPTO) Board of Patent Appeals and Interferences decision ("the Decision") reversing all previous rejections in the US 6,573,099 (the '099 Graham patent) appeal.

4 Oct 2010

Maven Semantic updates Urinary Incontinence research database

Maven Semantic announces updates to their Urinary Incontinence research database.

4 Oct 2010

Scientists discover c-Abl protein role in Parkinson's disease progression

Johns Hopkins scientists have discovered that the over-activation of a single protein may shut down the brain-protecting effects of a molecule and facilitate the most common form of Parkinson's disease.

4 Oct 2010

Researchers find new way to increase number of blood-forming stem cells when grown outside the body

One of the major challenges in stem cell transplants is how to obtain sufficient numbers of these remarkably rare cells to put into patients. To help overcome this issue, research from the Centenary Institute, Royal Prince Alfred Hospital and the University of Sydney has found a way to increase the number of blood-forming stem cells when growing them outside of the body.

4 Oct 2010

Researchers identify ways to predict embryonic developmental success

Two-thirds of all human embryos fail to develop successfully. Now, in a new study, researchers at the Stanford University School of Medicine have shown that they can predict with 93 percent certainty which fertilized eggs will make it to a critical developmental milestone and which will stall and die. The findings are important to the understanding of the fundamentals of human development at the earliest stages, which have largely remained a mystery despite the attention given to human embryonic stem cell research.

4 Oct 2010

Researchers create new cell lines from mesenchymal stem cells

Biomedical researchers at the University at Buffalo have engineered adult stem cells that scientists can grow continuously in culture, a discovery that could speed development of cost-effective treatments for diseases including heart disease, diabetes, immune disorders and neurodegenerative diseases.

4 Oct 2010

AVEO Pharmaceuticals to present tivozanib Phase 2 study results at IKCS Symposium

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that previously reported results from its Phase 2 study evaluating tivozanib for the treatment of advanced renal cell carcinoma (RCC) will be presented at the Ninth International Kidney Cancer Symposium (IKCS) in Chicago, Illinois, October 1-2, 2010.

4 Oct 2010

BCBC awards grant for cell therapy research in type 1 diabetes

Maike Sander, MD, associate professor of pediatrics and cellular & molecular medicine at the University of California, San Diego School of Medicine has been awarded nearly $5 million by the Beta Cell Biology Consortium (BCBC) to lead an interdisciplinary team in cell therapy research for type 1 diabetes.

4 Oct 2010

PET imaging technique helps early treatment response assessment for cisplatin-resistant ovarian cancer

Research reported in the October issue of The Journal of Nuclear Medicine (JNM) shows that a molecular imaging technique may prove useful in early assessment of treatment response for cisplatin-resistant ovarian cancer.

4 Oct 2010

Researchers find gene variations in PDE11A enzyme can increase risk for prostate cancer

Researchers at the National Institutes of Health have found that variations in a gene for an enzyme involved in cell energy metabolism appear to increase the risk for prostate cancer.

4 Oct 2010

Cell News and Research

Corning acquires Plaslab

Onconova enters agreement with FDA for Estybon Phase 3 trial SPA

Mylan subsidiary receives FDA approval for Fludarabine Phosphate Injection ANDA

JASH journal added to MEDLINE collection

Merck's boceprevir Phase III studies for HCV to be presented at 61st AASLD

Advanced BioHealing to present industry experience at 2010 World Stem Cell Summit

Noninvasive embryo assessment technology may improve success rates for in vitro fertilization procedures

Rate of chemotherapy administration for NSCLC more than twice that reported by SEER

NIH to award $64M under Transformative Research Projects program

Study demonstrates potential of nontoxic envelope proteins as an alternative to pseudotype lentiviral vectors

Benitec announces USPTO's reversal of all previous rejections in '099 Graham patent appeal

Maven Semantic updates Urinary Incontinence research database

Scientists discover c-Abl protein role in Parkinson's disease progression

Researchers find new way to increase number of blood-forming stem cells when grown outside the body

Researchers identify ways to predict embryonic developmental success

Researchers create new cell lines from mesenchymal stem cells

AVEO Pharmaceuticals to present tivozanib Phase 2 study results at IKCS Symposium

BCBC awards grant for cell therapy research in type 1 diabetes

PET imaging technique helps early treatment response assessment for cisplatin-resistant ovarian cancer

Researchers find gene variations in PDE11A enzyme can increase risk for prostate cancer

What are the challenges of cell line development? eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics